We have located links that may give you full text access.
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Chronic administration of apple polyphenols ameliorates hyperglycaemia in high-normal and borderline subjects: A randomised, placebo-controlled trial.
Diabetes Research and Clinical Practice 2017 July
AIMS: We previously reported that apple polyphenols (AP) and their major active components, procyanidins, had beneficial effects on glucose homeostasis and diabetes in diabetic ob/ob mice. The present study was performed to evaluate the effects of chronic AP administration on glucose tolerance in high-normal and borderline human subjects.
METHODS: Subjects (n=65) with a fasting plasma glucose (FPG) level of 100-125mg/dL determined during a recent health check-up were randomised to receive tablets containing AP (600mg/day) or placebo tablets for 12weeks in a double-blinded, placebo-controlled clinical trial. The primary outcome was insulin resistance, assessed using a 75g oral glucose tolerance test (OGTT).
RESULTS: The 12-week chronic administration of AP significantly reduced the increase in glucose at 30-min post-75g OGTT (OGTT30-min glucose ) value, compared to the placebo regimen. Furthermore, in a subgroup of the high-normal (FPG value, 100-109mg/dL; 2-h post-75g OGTT glucose (OGTT2-h glucose ) value, <140mg/dL) and borderline (FPG value, 110-125mg/dL; OGTT2-h glucose value, <140mg/dL and FPG value, <126mg/dL; OGTT2-h glucose value, 140-199mg/dL) subjects, OGTT30-min glucose value in the AP group (164.0±7.4mg/dL) was significantly lower than that of the placebo group (194.7±10.4mg/dL, p<0.05). No significant changes in the other lipid parameters and cytokine levels were observed.
CONCLUSIONS: Chronic AP administration significantly improved impaired glucose tolerance in high-normal and borderline subjects. Larger and/or longer-term scale human studies are required to confirm the potential glucose homeostasis of AP.
METHODS: Subjects (n=65) with a fasting plasma glucose (FPG) level of 100-125mg/dL determined during a recent health check-up were randomised to receive tablets containing AP (600mg/day) or placebo tablets for 12weeks in a double-blinded, placebo-controlled clinical trial. The primary outcome was insulin resistance, assessed using a 75g oral glucose tolerance test (OGTT).
RESULTS: The 12-week chronic administration of AP significantly reduced the increase in glucose at 30-min post-75g OGTT (OGTT30-min glucose ) value, compared to the placebo regimen. Furthermore, in a subgroup of the high-normal (FPG value, 100-109mg/dL; 2-h post-75g OGTT glucose (OGTT2-h glucose ) value, <140mg/dL) and borderline (FPG value, 110-125mg/dL; OGTT2-h glucose value, <140mg/dL and FPG value, <126mg/dL; OGTT2-h glucose value, 140-199mg/dL) subjects, OGTT30-min glucose value in the AP group (164.0±7.4mg/dL) was significantly lower than that of the placebo group (194.7±10.4mg/dL, p<0.05). No significant changes in the other lipid parameters and cytokine levels were observed.
CONCLUSIONS: Chronic AP administration significantly improved impaired glucose tolerance in high-normal and borderline subjects. Larger and/or longer-term scale human studies are required to confirm the potential glucose homeostasis of AP.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app